Mirati Therapeutics (DB:26M) - Cours de l'action, nouvelles et analyse

26M Aperçu des actions

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. Plus de détails

26M analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	2/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Se négocie à 87.2% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 42.24% par an

Analyse des risques

Les actionnaires ont été dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Ventes d'initiés importantes au cours des 3 derniers mois

Mirati Therapeutics, Inc. Concurrents

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€857.2m

Heidelberg Pharma

XTRA:HPHA

€105.8m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.1b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Mirati Therapeutics
Historique des cours de bourse
Prix actuel de l'action	US$53.30
Plus haut sur 52 semaines	US$59.46
Plus bas sur 52 semaines	US$25.13
Bêta	0.77
1Variation sur 1 mois	0.95%
Variation sur 3 mois	2.74%
Variation sur 1 an	22.25%
3Variation sur 3 ans	-69.72%
Variation sur 5 ans	-1.55%
Évolution depuis l'introduction en bourse	247.67%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	26M	DE Biotechs	DE Marché
7D	-2.0%	-1.1%	1.1%
1Y	22.2%	-18.8%	7.2%

Rendement vs Industrie: 26M a dépassé le secteur German Biotechs qui a rapporté -18.8 % au cours de l'année écoulée.

Rendement vs marché: 26M a dépassé le marché German qui a rapporté 7.2 % au cours de l'année écoulée.

Volatilité des prix

Is 26M's price volatile compared to industry and market?
26M volatility
26M Average Weekly Movement	1.4%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: 26M n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 26M a diminué de 10% à 1% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Mirati Therapeutics se comparent-ils à sa capitalisation boursière ?
26M statistiques fondamentales
Capitalisation boursière	€3.79b
Bénéfices(TTM)	-€668.10m
Recettes(TTM)	€35.15m

107.8x

Ratio P/S

-5.7x

Ratio P/E

Le site 26M est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
26M compte de résultat (TTM)
Recettes	US$38.19m
Coût des recettes	US$510.48m
Marge brute	-US$472.29m
Autres dépenses	US$253.59m
Les revenus	-US$725.88m

Derniers bénéfices déclarés

Sep 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-10.35
Marge brute	-1,236.66%
Marge bénéficiaire nette	-1,900.65%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de 26M?

Voir les performances historiques et les comparaisons

26M Aperçu des actions

Récompenses

Analyse des risques

Mirati Therapeutics, Inc. Concurrents

XTRA:BIO3

€1.3b

XTRA:FYB

€857.2m

XTRA:HPHA

€105.8m

XTRA:1SXP

€4.1b

Historique des prix et performances

Nouvelles et mises à jour récentes

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Insufficient new directors

Second quarter 2023 earnings released: US$3.04 loss per share (vs US$3.18 loss in 2Q 2022)

New minor risk - Insider selling

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Chief Financial Officer recently sold €161k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO & Director recently sold €125k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold €160k worth of stock

Executive VP & Chief Scientific Officer recently sold €98k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Executive VP & Chief Scientific Officer recently sold €148k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Mirati Therapeutics, Inc. Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C -Mutated Gastrointestinal Cancers

Chief Commercial Officer recently sold €67k worth of stock

Chief Commercial Officer recently sold €235k worth of stock

Chief Scientific Officer recently sold €139k worth of stock

High number of new directors

High number of new directors

Independent Director Michael Grey has left the company

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2000 Growth Index

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation

Chief Scientific Officer recently sold €55k worth of stock

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Rendement pour les actionnaires

Volatilité des prix